Amgen (AMGN): FY25 Q1 earnings call, May 1, 2025
No Kalshi or Polymarket word markets were listed for Amgen’s May 1, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
12 matches for “Oral”; 5 quoted, at least 25 words apart.
…will hold up? And secondly, that there's a competitor out there -- oral data, which apparently is going to have a huge market share. And…
…you if you wouldn't mind to weigh in on the development of oral medicines and their importance. Mike, we feel very confident -- I feel…
…surely underscore that the design is constructed to deliver competitive, both efficacy and tolerability in patients with and without type 2 diabetes. Murdo about oral?
…haven't seen necessarily the same degree of weight loss being achievable with orals as we've seen with MariTide. And of course, MariTide really, given its…
…products in our early pipeline that are both large molecule, small molecule, oral and self-administered incretin and non-incretins. So we really are looking at oral…
Agents: this page as TSV at /api/v1/appearances/amgen:2025-05-01:earnings_call · words: /api/v1/brief?appearance=amgen:2025-05-01:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP